DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia

Information source: GWT-TUD GmbH
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 2 Diabetes Mellitus; Diabetic Foot; Critical Limb Ischemia

Phase: N/A

Status: Terminated

Sponsored by: GWT-TUD GmbH

Official(s) and/or principal investigator(s):
S. Schellong, Prof.Dr.med., Principal Investigator, Affiliation: Staedt. KH Dresden-Friedrichstadt

Summary

Diabetic foot syndrome (DFS) is a disease caused by neurogenic (concerning the nervous system), vascular, mechanic and metabolic factors, which are further complicated by an impairment of the immune system and a corresponding increase in the risk for infections. Results from clinical trials about the efficacy of interventions aimed at reducing the number of patient-relevant end points are of limited comparability due to the heterogenity of patient characteristics. By their very nature, randomized clinical trials (RCT) can only focus on a limited section of the wide range of possible intervention regimes. In clinical practice, however, a number of patients with dfs will never have been part of a clinical trial. Furthermore, there are only very few contemporary registers for this indication from which conclusions with regard to the comparative merits of different therapeutic strategies may be drawn. The register was conceived to find out to which extent RCT patients are representative for the overall patient collective with dfs and critical limb ischemia and to evaluate the therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase versus placebo is imbedded in the register.

Clinical Details

Official title: Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: duration of survival without major amputation

Secondary outcome:

major amputation

total mortality

Detailed description: August-1 is a register to find out to which extent RCT patients are representative for the overall patient collective with dfs and critical limb ischemia and to evaluate the therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase versus placebo is imbedded in the register.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diabetic patients with dfs and critical limb ischemia

- age 18 and older

Exclusion Criteria:

- less than 1 year life expectancy

- prior major amputation

- planned major expectation

- prior treatment of the current episode of dfs with urokinase

- mechanical heart valve replacement

- cerebral event with changes in CT during the last three months

- non-remediated proliferating retinopathy

- uncontrolled hypertension (systolic > 180 mmHg, diastolic > 100 mmHg)

- hemorrhagic diathesis (spontaneous quick value < 50%, spontaneous ptt > 40 sec,

thrombocytes < 100 gpt/l)

- acute gastrointestinal bleeding or ulcers during the last 4 weeks

- prior reverse bypass operation

- concomitant participation in other clinical trials

- insufficient compliance

- premenopausal women not using a safe method of contraception (i. e. IUD, hormone

implants, hormone depot injection, combined pill (estrogens and gestagens), vaginal ring or vasectomized partner).

Locations and Contacts

Krankenhaus Dresden-Friedrichstadt, Dresden, Sachse 01076, Germany
Additional Information

Starting date: June 2010
Last updated: April 4, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017